AI Portfolio Summary
In 2025 Q4, Aisling Capital Management LP maintained a portfolio of 15 distinct positions. The most significant new addition to the portfolio was Urogen Pharma Ltd. (, which now represents 0.53% of the total fund value. Conversely, Aisling Capital Management LP completely exited their position in Nuvation Bio Inc. (N.
Total Positions
15
Quarter
2025 Q4
Top Holding
BBIO (81.3%)
Top 10 Concentration
99.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-15 of 15
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharm...
|
Healthcare | 81.29% | 69.29% |
#1
Prev: #1
|
6.5 | -1,000,000 | -16.4% |
P
S
|
5,089,611 | $389,304,345 | 2019 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
Syndax Pharmace...
|
Healthcare | 5.78% | 4.44% |
#2
1
Prev: #3
|
4.8 | no change | no change |
P
S
|
1,316,806 | $27,666,094 | 2020 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 4.82% | 2.39% |
#3
2
Prev: #5
|
3.9 | no change | no change |
P
S
|
1,472,331 | $23,086,150 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 2.00% | 1.97% |
#4
2
Prev: #6
|
2.3 | no change | no change |
P
S
|
568,919 | $9,574,907 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CMPS
Compass Pathway...
|
Healthcare | 1.73% | 1.50% |
#5
2
Prev: #7
|
2.2 | no change | no change |
P
S
|
1,198,418 | $8,269,084 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBOT
BridgeBio Oncol...
|
Healthcare | 1.48% | 1.43% |
#6
2
Prev: #8
|
1.6 | no change | no change |
P
S
|
564,625 | $7,069,105 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CALC
CalciMedica, In...
|
Healthcare | 0.72% | 0.35% |
#7
4
Prev: #11
|
1.3 | no change | no change |
P
S
|
521,114 | $3,434,141 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
Scholar Rock Ho...
|
Healthcare | 0.71% | 0.63% |
#8
2
Prev: #10
|
1.3 | no change | no change |
P
S
|
77,031 | $3,393,216 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMEA
Biomea Fusion I...
|
Healthcare | 0.53% | 0.91% |
#9
Prev: #9
|
1.2 | no change | no change |
P
S
|
2,048,757 | $2,540,459 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
URGN
Urogen Pharma L...
|
Healthcare | 0.53% | — |
#10
Prev: #—
|
3.7 | 108,000 | no change |
NEW
|
108,000 | $2,529,360 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 0.27% | 0.18% |
#11
1
Prev: #12
|
1.1 | no change | no change |
P
S
|
434,455 | $1,307,710 | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRKR
Marker Therapeu...
|
Healthcare | 0.10% | 0.06% |
#12
1
Prev: #13
|
1.0 | no change | no change |
P
S
|
325,370 | $484,801 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OKUR
OnKure Therapeu...
|
Healthcare | 0.05% | 0.05% |
#13
1
Prev: #14
|
1.0 | no change | no change |
P
S
|
88,607 | $256,960 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVB
Nuvation Bio In...
|
Healthcare | 0.00% | 2.40% |
Sold All 😨
(Was: #4) |
0.0 | -2,960,659 | -100.0% |
CLOSED
|
— | $— | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
Verona Pharma p...
|
Unknown | 0.00% | 14.39% |
Sold All 😨
(Was: #2) |
0.0 | -615,352 | -100.0% |
CLOSED
|
— | $— | 2018 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-15 of 15 holdings